創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
19/08/13 GEM097 Factor VIIa derivative Bypassing therapy in hemophilia with inhibitors i.v. Protein
IND ready GEM097 is rFVIIa fused to transferrin and has longer half-lives than rFVIIa in rats and monkeys. A cleavable linker between rFVIIa and trasferrin of GEM097 allows minimal reducuction of FVIIa activity due to fusion. Preclinical (GLP) toxicity studies did not show any toxic evidence in rats or monkeys. 問合せ
19/07/31 GEM096 Progesterone receptor agonist Recurrent preterm birth Oral Small molecule
Phase 2 completed Potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. An end of Phase 2 meeting was completed with the FDA.
問合せ
19/07/31 GEM095 Androgen receptor agonist NASH, Cirrhosis Oral Small molecule
Phase 1 An oral prodrug of bioidentical testosterone that is being developed as a treatment of cirrhotic non-alcoholic steatohepatitis (NASH). 問合せ
19/07/31 GEM094 Androgen receptor agonist NASH, Pre-Cirrhosis Oral Small molecule
Phase 2 ongoing An oral prodrug of bioidentical testosterone that is being developed as a treatment of non-alcoholic steatohepatitis (NASH) and is being studied in the LifT Phase 2 clinical study in biopsy confirmed NASH subjects. 問合せ
19/07/31 GEM093 Androgen receptor agonist Hypogonadism Refer to Note Small molecule
Phase 2 completed Route: Oral (QD)

A novel next generation oral prodrug of testosterone with potential for once-daily oral dosing that has completed Phase 2 testing.
問合せ
19/07/31 GEM092 Androgen receptor agonist Hypogonadism Refer to Note Small molecule
Refer to Note Route: Oral (BID)
Development stage: Phase 3 (a few months before PDUFA date)

A novel oral prodrug of testosterone that is designed to help restore normal testosterone levels in hypogonadal men. GEM092 was well tolerated and met the primary end-points in Phase 3 testing with twice daily dosing. Easy to use for patients and physicians to prescribe due to fixed doing regimen.
問合せ
19/07/16 GEM091 Prevention of protein aggregation via increased intracellular ATP and increase of expression of tyrosine hydroxylase (TH) Parkinson's disease Oral/nasal Small molecule
Preclinical New treatment for Parkinson's disease. GEM091 increases intracellular ATP level and ATP is reported to boost protein solubility. GEM091 increases TH expression and dopamine production, reverses paraquat induced PD symptoms and improves behavior of 6-OHDA treated mice. 問合せ
19/07/16 GEM090 Increase cellular ATP and promote wound healing Refer to Note Topical Small molecule
Preclinical Indication: Epidermolysis Bullosa (EB)

Increasing cellular ATP and speeding up the healing of wounds by promoting the migration of epithelia cells in the skin of wounds.
Expected to shorten wound healing time and improve EB patients' QOL with a formulation optimized for EB treatment. Moreover, maybe reduces the risk of squamous cell carcinoma which is highly related to Dystrophic EB patients.
問合せ
19/07/12 GEM089 Inhibition of pro-cytokines, enhancement of growth factor PDGF Alzheimer's disease and vascular dementia Topical Botanical
Phase 2 Small molecules from soybean extract.
MOA is different from Tau and Amyloid mechanisms.
Effective in AlCl3 induced Alzheimer-like dementia model and bilateral common carotid artery occlusion induced vascular dementia model.
In Phase 2 study, MMSE and ADAS-Cog for patients without any dementia medication indicated that 70-85% patients improved at weeks 4 and 12.
問合せ
19/07/12 GEM088 SSRI with agonist-antagonistic action on 5-HT receptors Urinary incontinence Oral Small molecule
Phase 3 ready Repositioning from another indication and has already a proven record of good safety in more than 300 patients with further 300 treated in phase 2. It has shown therapeutic activity in animal models of both stress and urge urinary incontinence.
In phase 2 trials, clinically meaningful effects in mixed incontinence were shown as well as very good tolerability. The compound is ready to enter phase 3.
問合せ